Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28390904 | 0.86 | NAMPT (0.47) | NAMPTCYP17A1RAB9AAAK1KDM4E | |
| SCHEMBL18038575 | 0.84 | KDM4C (0.39) | AAK1KDM4EALDH1A1GLAGAA | |
| SCHEMBL38664167 | 0.81 | HDAC1 (0.47) | RAB9A | |
| SCHEMBL4075291 | 0.79 | NAMPT (0.42) | NAMPTCYP17A1RAB9ALATS1AAK1 | |
| SCHEMBL5746021 | 0.75 | NAMPT (0.47) | NAMPTCYP17A1RAB9AAAK1KDM4E | |
| SCHEMBL15432248 | 0.74 | KDM4E (0.51) | KDM4EALDH1A1GLAGAA | |
| SCHEMBL18522430 | 0.73 | NAMPT (0.50) | NAMPTCYP17A1RAB9ALATS1ATR | |
| SCHEMBL15986887 | 0.73 | PTGS1 (0.44) | NAMPTRAB9AAAK1ATR | |
| SCHEMBL7484295 | 0.73 | NAMPT (0.43) | NAMPTCYP17A1RAB9AAAK1KDM4E | |
| SCHEMBL23155544 | 0.71 | NAMPT (0.46) | NAMPTCYP17A1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022723-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2018-01-25 | — | — | US | disclosed |
| WO-2016137832-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022723-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | NAMPT 2277/4885CYP17A1 1160/4885RAB9A 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.